Global Short Bowel Syndrome Market: Industry Insights, Trends, and Strategic Outlook

Overview of Short Bowel Syndrome Market

The Short Bowel Syndrome (SBS) market is witnessing substantial growth due to the rising prevalence of gastrointestinal disorders, increasing awareness of rare diseases, and advancements in specialized therapeutics. Short Bowel Syndrome is a rare condition typically caused by the surgical removal of a large portion of the small intestine, leading to poor nutrient absorption and various complications.

The Global Short Bowel Syndrome Market is valued at USD 1.76 Billion in 2024 and is projected to reach a value of USD 3.66 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 6.91% between 2025 and 2035. The market is primarily driven by the growing number of surgical interventions, the emergence of innovative drugs such as GLP-2 analogs, and the expansion of nutrition management services. Rising investment in R&D and increasing regulatory approvals for orphan drugs are also catalyzing market expansion globally.

Get Ahead with Our Report: Request Your Sample Now!

Market Dynamics

The dynamics of the Short Bowel Syndrome market are influenced by a range of interrelated factors, including medical, economic, technological, and regulatory dimensions. One of the most significant drivers is the increasing incidence of gastrointestinal diseases and surgeries that lead to SBS, particularly in neonates and adults with Crohn’s disease or cancer-related resections. With a growing population of patients needing long-term nutritional and pharmaceutical support, demand for effective therapies such as teduglutide and somatropin has surged. Moreover, improved diagnostic capabilities and rising healthcare expenditure are accelerating early diagnosis and better disease management.

On the other hand, the market dynamics are challenged by the high cost of treatment and limited patient awareness in emerging economies. Even though SBS is a rare disease, the cost burden on patients for lifelong therapy—including parenteral nutrition, specialized drugs, and hospital visits—can be considerable. Regulatory support, such as orphan drug designation by the FDA and EMA, has helped fast-track innovation in the space, encouraging biotech firms and pharma giants to invest in this niche market. However, market penetration remains restricted due to clinical complexities and inconsistent healthcare access across regions.

Top Trends in the Short Bowel Syndrome Market

One of the most prominent trends in the Short Bowel Syndrome market is the rapid advancement of GLP-2 analogs, especially the growing adoption of teduglutide (Gattex/Revestive), which enhances intestinal absorption and reduces dependence on parenteral nutrition. These therapies are transforming the management of SBS, providing patients with improved quality of life and reduced healthcare burden. Another major trend is the increasing interest in regenerative medicine, which aims to restore intestinal function through tissue engineering and stem cell therapies.

Digital health integration is also shaping the SBS treatment landscape, with telemedicine and mobile apps helping monitor patients on home parenteral nutrition (HPN), manage complications, and ensure medication adherence. Collaborations between hospitals and pharmaceutical companies to develop patient-centric programs for chronic disease management are also gaining momentum. Furthermore, market players are actively investing in awareness campaigns and educational programs to empower healthcare professionals and patients with timely knowledge about SBS.

Research and development are being focused on novel drug formulations with improved efficacy and minimal side effects. Additionally, the increased use of real-world evidence (RWE) and patient registries is aiding in better understanding disease progression and therapeutic outcomes, thereby influencing reimbursement decisions and regulatory pathways.

Competitive Landscape

• TAKEDA Inc (Japan)
• Nutrinia (Netherlands)
• OxThera (Sweden)
• VectivBio AG (Switzerland)
• Ardelyx (US)

Top Report Findings

• Teduglutide remains the gold standard treatment, capturing more than 40% of the treatment market share.
• North America dominates the global SBS market with over 55% revenue share in 2024.
• The pediatric SBS segment is growing at a CAGR of 7.1% due to increasing neonatal intestinal surgeries.
• Rising adoption of home parenteral nutrition (HPN) is driving demand for long-term management programs.
• Pipeline drugs with extended GLP-2 action and minimal side effects are expected to enter the market by 2027.
• Orphan drug incentives have led to over 10 novel molecules being in different stages of clinical development.
• Increasing partnerships between pharma firms and digital health providers to enhance patient monitoring is gaining traction.
• Asia-Pacific is projected to witness the fastest CAGR of 8.5% during 2025–2035, driven by better diagnosis and growing healthcare access.

Market Segmentation

By Drug Class

• GLP-2
• Growth Hormone (18.9%)
• Glutamine
• Others

By Region

• North America (U.S., Canada, Mexico) (36.7%)
• Europe (Germany, France, U.K., Italy, Spain, Nordic Countries, Benelux Union, Rest of Europe)
• Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, South-East Asia, Rest of Asia Pacific)
• Latin America (Brazil, Argentina, Rest of Latin America)
• Middle East & Africa

Challenges in the Short Bowel Syndrome Market

Despite growing awareness and innovation, the SBS market faces several critical challenges. Foremost among them is the high cost of treatment, which includes expensive biologics like teduglutide and long-term parenteral nutrition, making it unaffordable for many patients, particularly in low-income regions. Moreover, managing SBS requires specialized care teams, coordinated services, and nutritional monitoring, which are not widely available in rural or underdeveloped areas. Limited awareness among patients and even general practitioners leads to delayed diagnoses and suboptimal treatment approaches. Additionally, potential side effects from long-term drug use, such as intestinal neoplasia risks from GLP-2 analogs, raise concerns for both patients and healthcare providers. Clinical complexity, coupled with lack of standardized treatment protocols, further hampers consistent outcomes.

Opportunities in the Short Bowel Syndrome Market

Amidst the challenges, several opportunities are emerging in the SBS market. Rising investments in rare disease research, backed by government support and global collaborations, are opening new avenues for drug development. Orphan drug designations, regulatory fast tracks, and priority review vouchers are encouraging pharmaceutical companies to invest in high-cost, low-volume therapies. The advent of personalized medicine and gene-based therapy platforms is offering promising avenues for targeting the root causes of SBS. Moreover, expansion of telehealth services is creating opportunities for remote patient management, especially in HPN monitoring and nutritional counseling. As digital health platforms mature, they will likely drive greater adherence and better patient outcomes. Collaborations between hospitals, insurers, and biopharma firms can also improve affordability and access, especially in emerging markets.

Detailed Market Study: Full Report and Analysis

Key Questions Answered in Short Bowel Syndrome Market Report

1. What is the current market size of the Short Bowel Syndrome market?
2. What factors are driving the growth of SBS treatments globally?
3. How effective are GLP-2 analogs in reducing parenteral nutrition dependency?
4. What are the major challenges faced by SBS patients and healthcare providers?
5. Which patient demographics are most affected by Short Bowel Syndrome?
6. What are the key technological trends shaping the SBS treatment landscape?
7. How is North America maintaining its dominance in the global SBS market?
8. What pipeline therapies are expected to impact the SBS market in the next 5 years?

Regional Analysis: Focus on North America

North America is the leading region in the global Short Bowel Syndrome market, accounting for over 55% of total revenue share. The United States, in particular, is driving market dominance due to its well-established healthcare infrastructure, strong regulatory support for orphan drugs, and the early adoption of innovative treatments like teduglutide. High awareness levels among healthcare professionals and patients, coupled with advanced diagnostic capabilities, contribute to early and effective disease management. Moreover, robust reimbursement policies for rare diseases, including coverage for parenteral nutrition and biologics, make advanced SBS treatments more accessible.

The region is also home to several leading pharmaceutical companies and research institutions that actively engage in SBS drug development and clinical trials. The presence of specialized intestinal rehabilitation centers, particularly in pediatric care, ensures that both acute and chronic SBS cases receive tailored treatment. North America is witnessing increasing integration of digital health in SBS management, with telehealth services aiding in remote patient monitoring and nutritional support. These factors collectively position the region as a hub for innovation, market growth, and patient care excellence in the Short Bowel Syndrome space.